Veronica R Placencio-Hickok1, Marie Lauzon2, Natalie Moshayedi1, Michelle Guan1, Sungjin Kim2, Nicholas Nissen3, Simon Lo1, Stephen Pandol1, Brent K Larson4, Jun Gong1, Andrew E Hendifar1, Arsen Osipov5. 1. Gastrointestinal and Neuroendocrine Malignancies, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. 2. Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. 3. Liver Transplantation and Hepatopancreatobiliary Surgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. 4. Department of Pathology and Laboratory Medicine, 8700 Beverly Blvd., Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 5. Gastrointestinal and Neuroendocrine Malignancies, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address: Arsen.Osipov@cshs.org.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with poor survival. The dense desmoplastic stroma in PDAC contributes to treatment resistance. Among the components comprising the tumor stroma, hyaluronan (HA) has been demonstrated to play a critical role in tumor progression and survival. Previous preliminary studies have suggested differences in HA expression in primary and metastatic foci of PDAC. However, the effects of treatment and location of HA expression as a biomarker signature remain unknown; this study sought to compare HA expression in primary and metastatic sites of PDAC. METHODS: Tissue from primary and metastatic PDACs were obtained from Cedars-Sinai Medical Center along with associated clinical data. Tissue slides were stained for H&E, HA, and CD44. Associations between HA levels and the evaluated variables were examined including progression free survival and overall survival. RESULTS: HA score was significantly higher in primary PDACs compared to sites of metastases (p = 0.0148). Within the metastases, HA score was significantly higher in liver metastases compared to metastases at other sites (p = 0.0478). In the treatment-naive liver metastasis cohort, patients with HA high status had decreased progression free survival and overall survival compared to patients with HA low status (p = 0.0032 and p = 0.0478, respectively). CONCLUSIONS: HA score is variable between primary PDAC, PDAC metastatic to the liver, and PDAC metastatic to other sites. Within liver metastases, patients with HA high status had decreased progression free survival and overall survival compared to patients with HA low status. HA levels can serve as a potential biomarker to guide pancreatic cancer treatments and trial design for agents targeting the stroma.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with poor survival. The dense desmoplastic stroma in PDAC contributes to treatment resistance. Among the components comprising the tumor stroma, hyaluronan (HA) has been demonstrated to play a critical role in tumor progression and survival. Previous preliminary studies have suggested differences in HA expression in primary and metastatic foci of PDAC. However, the effects of treatment and location of HA expression as a biomarker signature remain unknown; this study sought to compare HA expression in primary and metastatic sites of PDAC. METHODS: Tissue from primary and metastatic PDACs were obtained from Cedars-Sinai Medical Center along with associated clinical data. Tissue slides were stained for H&E, HA, and CD44. Associations between HA levels and the evaluated variables were examined including progression free survival and overall survival. RESULTS: HA score was significantly higher in primary PDACs compared to sites of metastases (p = 0.0148). Within the metastases, HA score was significantly higher in liver metastases compared to metastases at other sites (p = 0.0478). In the treatment-naive liver metastasis cohort, patients with HA high status had decreased progression free survival and overall survival compared to patients with HA low status (p = 0.0032 and p = 0.0478, respectively). CONCLUSIONS: HA score is variable between primary PDAC, PDAC metastatic to the liver, and PDAC metastatic to other sites. Within liver metastases, patients with HA high status had decreased progression free survival and overall survival compared to patients with HA low status. HA levels can serve as a potential biomarker to guide pancreatic cancer treatments and trial design for agents targeting the stroma.
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: K Mima; T Beppu; T Ishiko; A Chikamoto; S Nakagawa; H Hayashi; M Watanabe; K Sakamaki; H Baba Journal: Br J Surg Date: 2014-01-20 Impact factor: 6.939
Authors: Ashton A Connor; Robert E Denroche; Gun Ho Jang; Mathieu Lemire; Amy Zhang; Michelle Chan-Seng-Yue; Gavin Wilson; Robert C Grant; Daniele Merico; Ilinca Lungu; John M S Bartlett; Dianne Chadwick; Sheng-Ben Liang; Jenna Eagles; Faridah Mbabaali; Jessica K Miller; Paul Krzyzanowski; Heather Armstrong; Xuemei Luo; Lars G T Jorgensen; Joan M Romero; Prashant Bavi; Sandra E Fischer; Stefano Serra; Sara Hafezi-Bakhtiari; Derin Caglar; Michael H A Roehrl; Sean Cleary; Michael A Hollingsworth; Gloria M Petersen; Sarah Thayer; Calvin H L Law; Sulaiman Nanji; Talia Golan; Alyssa L Smith; Ayelet Borgida; Anna Dodd; David Hedley; Bradly G Wouters; Grainne M O'Kane; Julie M Wilson; George Zogopoulos; Faiyaz Notta; Jennifer J Knox; Steven Gallinger Journal: Cancer Cell Date: 2019-01-24 Impact factor: 31.743
Authors: Laurence Jadin; Lei Huang; Ge Wei; Qiping Zhao; Arnold B Gelb; Gregory I Frost; Ping Jiang; H Michael Shepard Journal: J Histochem Cytochem Date: 2014-06-02 Impact factor: 2.479
Authors: Ramesh K Ramanathan; Shannon L McDonough; Philip A Philip; Sunil R Hingorani; Jill Lacy; Jeremy S Kortmansky; Jaykumar Thumar; E Gabriela Chiorean; Anthony F Shields; Deepti Behl; Paul T Mehan; Rakesh Gaur; Tara Seery; Katherine A Guthrie; Howard S Hochster Journal: J Clin Oncol Date: 2019-02-28 Impact factor: 50.717